Zacks Investment Research cut shares of Mediwound Ltd (NASDAQ:MDWD) from a buy rating to a hold rating in a report released on Saturday morning, Market Beat.com reports.

According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “

Several other research firms also recently issued reports on MDWD. Brean Capital assumed coverage on shares of Mediwound in a research note on Friday, January 8th. They set a buy rating and a $20.00 price target for the company. Oppenheimer reaffirmed an outperform rating and set a $13.00 price target on shares of Mediwound in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Mediwound presently has a consensus rating of Buy and a consensus price target of $13.65.

Mediwound (NASDAQ:MDWD) traded up 5.30% during trading on Friday, hitting $6.76. 18,647 shares of the stock were exchanged. The firm’s 50-day moving average is $8.30 and its 200 day moving average is $8.03. The firm’s market cap is $147.71 million. Mediwound has a 52 week low of $5.00 and a 52 week high of $10.47.

Mediwound (NASDAQ:MDWD) last released its quarterly earnings results on Monday, January 25th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.13. The firm had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.40 million. During the same period in the prior year, the firm earned ($0.33) earnings per share. The business’s revenue was up 125.0% on a year-over-year basis. Analysts expect that Mediwound will post ($0.95) earnings per share for the current fiscal year.

MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing, manufacturing and commercializing products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. The Company’s biopharmaceutical product, NexoBrid, which is based on its patented proteolytic enzyme technology, represents a new paradigm in burn care management, and its clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier upon patient admission, without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary, targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.

12 Month Chart for NASDAQ:MDWD

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.